ASCO 2013 - Poster: Hematologic safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial

CHICAGO, IL USA ( - Presented by C. Parker,1 J. Garcia-Vargas,2 C.G. O’Bryan-Tear,3 F. Fang,2 N.J. Vogelzang4 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 Parker ra223 poster thumb

1The Royal Marsden NHS Foundation Trust, Sutton, UK; 2Bayer HealthCare, Montville, NJ, USA; 3Algeta ASA, Oslo, Norway; 4Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage






Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.